Pancreatic Cyst Follow-up study

The aim of the PACYFIC study is to establish the yield of regular pancreatic cyst surveillance, based on a recently published European Consensus statement, in terms of identified patients that require cyst resection, diagnosed malignancies, cyst evolution, and the perceived burden for participants. As a result, possible alternative, more (cost) effective, surveillance strategies may be identified. All patients with a pancreatic cyst, either newly or previously diagnosed, that require surveillance according to the opinion of
the treating physician, will be included. Surveillance will be based on the consensus statement, but at the discretion of the treating physician. Participating subjects will be asked to fill out online an questionnaire regarding the burden of surveillance after each follow-up visit.
The study will be implemented in several international centers in Europe.

To establish the yield of pancreatic cyst surveillance, based on the recently published European consensus statement, and to identify possible alternative, more (cost) effective, surveillance strategies.

The study will run for ten years.

Patients inclusion will be included from May 2014 until October 2023.

Follow-up will continue until April 2024.

The first analysis will be conducted in May 2017, after three years, to provide data for the MISCAN model.

Cyst surveillance will be performed at the hospital of origin, based on the recommendations of the consensus statement. Patients will be followed every 6 to 12 months by imaging studies (preferably Magnetic Resonance Imaging (MRI/MRCP), with endoscopic ultrasonography (EUS) as an alternative) and determination of serum CA 19.9 levels. Both treating physicians and participating subjects will provide outcome data, by filling out (on-line) case record forms (CRF) and questionnaires. Cyst management will remain in the hands of the treating physician.